Ori Biotech, Cell Therapies and AdCella join forces to tackle cell therapy manufacturing challenges

Parties to work together to deploy Ori Biotech’s automated cell therapy manufacturing platform, IRO®, in Asia Pacific and across AdCella’s cellular immunotherapy pipeline

• AdAlta’s AdCella, Ori Biotech and Cell Therapies sign MoU to bring Ori Biotech’s automated cell therapy manufacturing platform, IRO®, to Australia and the Asia Pacific region.

• IRO® tackles key CAR-T challenges: high cost, slow production, and inconsistent results.

• Next-generation automation promises: 10–50x higher throughput; shorter manufacturing times; 30–50% potential cost savings.

• Collaboration supports AdCella’s “East to West” strategy to deliver scalable, cost-effective cell therapies for solid cancers for global markets.

• Positions AdCella and CTPL as leaders in advanced cell therapy manufacturing in Asia-Pacific.

The video shows how IRO workd.

AdAlta CEO, Dr Tim Oldham said:

“Our strategy depends on showing partners that our therapies are not only effective but can be manufactured at scale, cost-effectively, and transferred easily between sites. IRO® offers the potential to deliver this across multiple products in our pipeline. This MoU is the first step toward accessing this exciting technology.”

Ori Biotech CEO, Jason Foster added:

“Getting CAR-T and other cell therapies into the clinic isn’t the biggest challenge anymore—it’s making them commercially viable. Current processes are too expensive and too hard to scale meaning that only 5% of patients globally get access to these life saving cell therapies. IRO® represents the new standard in manufacturing technology, enabling flexibility and automation from R&D all the way through to GMP. We’re thrilled to work with AdCella and CTPL to bring IRO® to Australia and the broader Asia Pacific Region.”

CTPL CEO, Dr Bev Menner said:

“Access to IRO® will help us attract commercial CAR-T programs to Australia and Asia, and accelerate development of scalable, lower cost therapies, improving patient access to these groundbreaking therapies.”